These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 22833573)
1. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573 [TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Huehls AM; Wagner JM; Huntoon CJ; Geng L; Erlichman C; Patel AG; Kaufmann SH; Karnitz LM Cancer Res; 2011 Jul; 71(14):4944-54. PubMed ID: 21613406 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. Geng L; Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM PLoS One; 2011; 6(12):e28862. PubMed ID: 22194930 [TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720 [TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154 [TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness. Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723 [TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337 [TBL] [Abstract][Full Text] [Related]
9. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Smith J; Tho LM; Xu N; Gillespie DA Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966 [TBL] [Abstract][Full Text] [Related]
10. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. Shibata H; Miuma S; Saldivar JC; Huebner K Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865 [TBL] [Abstract][Full Text] [Related]
11. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. Bauer M; Goldstein M; Heylmann D; Kaina B PLoS One; 2012; 7(6):e39956. PubMed ID: 22768182 [TBL] [Abstract][Full Text] [Related]
12. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551 [TBL] [Abstract][Full Text] [Related]
13. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Davidson D; Wang Y; Aloyz R; Panasci L Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related]
15. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726 [TBL] [Abstract][Full Text] [Related]
16. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576 [TBL] [Abstract][Full Text] [Related]
17. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Haynes B; Murai J; Lee JM Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007 [TBL] [Abstract][Full Text] [Related]
18. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. Gralewska P; Gajek A; Marczak A; Rogalska A J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968 [TBL] [Abstract][Full Text] [Related]
19. Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas. Chiappa M; Decio A; Guarrera L; Mengoli I; Karki A; Yemane D; Ghilardi C; Scanziani E; Canesi S; Barbera MC; Craparotta I; Bolis M; Fruscio R; Grasselli C; Ceruti T; Zucchetti M; Patterson JC; Lu RA; Yaffe MB; Ridinger M; Damia G; Guffanti F Cell Death Dis; 2024 Jul; 15(7):521. PubMed ID: 39039067 [TBL] [Abstract][Full Text] [Related]
20. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Ngoi NY; Sundararajan V; Tan DS Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]